Mythic Therapeutics’ innovative FateControl technology expands the potential of Antibody Drug Conjugates (ADCs) to destroy cancer and avoid normal cells.

Biotechnology

Education

Mythic Therapeutics

Mythic Therapeutics' headquarters in Waltham, MA, United States

Sandra Poole

Aashka Joshi

Ben Hutchins

Paul Basciano

Douglas Williams

Michael Vasconcelles

Scott Dylla

Bryan Roberts

Peter Hecht

Richard Gregory

John Lambert

Josh Kopelman

The Scientific Research Team at Mythic Therapeutics is dedicated to advancing the company's FateControl technology, focusing on the development and optimization of Antibody Drug Conjugates (ADCs) that specifically target and eliminate cancer cells while sparing healthy tissues. This team collaborates across disciplines, leveraging expertise in biology, antibody engineering, and protein sciences to drive innovative research and facilitate the translation of scientific discoveries into effective cancer therapies.

Scientific Research Team

The Leadership Team at Mythic Therapeutics is responsible for setting the strategic direction and oversight of the company’s innovative research and development initiatives. This team, comprising key executives such as the Chief Scientific Officer and COO, collaborates to drive the advancement of FateControl technology, ensuring that Antibody Drug Conjugates are effectively harnessed to target cancer cells while minimizing harm to normal tissues. Their leadership fosters a culture of innovation and scientific excellence critical for the company's mission to transform cancer treatment.

Leadership Team

Mythic Therapeutics

Org chart

Board & advisors

Teams

Scientific Research Team

Leadership Team

Offices

Mythic Therapeutics

Org chart

Board & advisors

Teams

Scientific Research Team

Leadership Team

Offices

Related companies